Notably, a recent breakthrough shows that NK2R agonists hold promise as candidates for obesity treatment since a long-acting NK2R agonist was shown to significantly reduce body weight, blood glucose, triglycerides, and cholesterol levels in diabetic, obese macaques, while also improving the insulin resistance (13). Here, TACR2 is linked to obesity disorder.